Cardio Diagnostics Holdings, Inc.

Cardio Diagnostics Holdings, Inc. specializes in developing and commercializing epigenetics-based clinical tests for cardiovascular disease. Their flagship product, Epi+Gen CHD, is a three-year symptomatic coronary heart disease risk assessment test. By leveraging epigenetics, the company provides innovative diagnostic solutions for identifying and managing cardiovascular conditions. Through the sale and distribution of their clinical tests, Cardio Diagnostics Holdings, Inc. generates revenue by catering to the growing demand for advanced cardiovascular disease risk assessment tools in the healthcare industry.

Products

• Epi+Gen CHD - symptomatic coronary heart disease risk assessment test